Silo Pharma Partners with Veloxity Labs for PTSD Treatment Study
Summary
Full Article
Silo Pharma (NASDAQ: SILO) has announced a partnership with Veloxity Labs to conduct GLP-compliant bioanalysis for its SPC-15 study, an intranasal treatment aimed at preventing PTSD. This collaboration marks a significant step towards submitting an investigational new drug application to the FDA by 2025. The success of this study could lead to a Phase 1 human clinical trial, offering new hope for individuals suffering from PTSD and stress-induced anxiety disorders.
The partnership underscores Silo Pharma's commitment to addressing underserved conditions through innovative therapeutics. SPC-15 represents a novel approach to treating PTSD, a condition that affects millions worldwide. The company's focus on psychedelic treatments and traditional therapies in new formulations highlights the evolving landscape of mental health treatment options.
For more details on Silo Pharma's initiatives and the SPC-15 study, visit https://ibn.fm/Bo8ag. Silo Pharma's dedication to research and development through collaborations with universities and independent laboratories positions it as a leader in the biopharmaceutical industry, particularly in the realm of CNS diseases and chronic pain conditions.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)